Validation of the Bleeding Academic Research Consortium

Reference: Circulation. 2012; 125:1424–143

Abstract: For many years all efforts applied to the optimization of percutaneous coronary intervention (PCI) were aimed specifically at reducing ischemic events risk through the advent of: 1) new devices (medicated stents), reducing restenosis rates, revascularization and 2) development of new drugs with a potent anti-platelet or anticoagulant such as clopidogrel or, more recently, prasugrel, ticagrelor, 2b3a inhibitors and direct thrombin inhibitors (DTIs) like bivalirudin among others. However, we have identified that in the mortality equation after PCI, ischemic risk plays an important role. Certainly, the risk of bleeding complications or bleeding itself has been recognized as dominant variables that directly influence the mortality rates of patients who have undergone PCI. Nevertheless, bleeding classification and definition has been very heterogeneous (TIMI, GUSTO, CURE, ACUITY, CURRENT OASIS, STEEPLE, GRACE, REPLACE 2)1, which has negative influences in accurately quantifying its incidence, severity and consequences (mortality). In this regard, the Bleeding Academic Research Consortium (BARC) 1 was recently formed, based on the idea of

More articles by this author

Download the Official SOLACI-CACI 2024 Congress APP

  DOWNLOAD THE OFFICIAL APP OF SOLACI-CACI 2024 Next Wednesday marks the beginning of SOLACI-CACI 2024! Download the Congress APP and discover the unmissable program of the...

Survey on Hemodynamics Centers in Latin America – SOLACI, Stent Save a Life! and South American Society of Cardiology Initiative

The treatment of ST-segment elevation myocardial infarction (STEMI) in Latin America is highly diverse. There are notable differences between countries and even among regions...

SOLACI-SBHCI 2023 Congress Has Begun!

Let the best begin! After a year of intense work, SOLACI-SBHCI 2023 Congress—the widest, most important event for interventional cardiologists in Latin America—has kicked...

SOLACI-SBHCI 2023 Congress Has Begun!

Let the best begin! After a year of intense work, SOLACI-SBHCI 2023 Congress—the widest, most important event for interventional cardiologists in Latin America—has kicked...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....